NCT06556238 Metabolism-Informed Care to Aid Alaska Native People to Quit Smoking (QUIT)
| NCT ID | NCT06556238 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Southcentral Foundation |
| Condition | Smoking Cessation |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-11-17 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-11-17 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to refine and pilot an intervention using the Nicotine Metabolite Ratio (NMR) to inform the selection of pharmacologic treatment to increase smoking abstinence among Alaska Native and American Indian people. This is a single-arm pilot trial to assess and improve acceptability and feasibility.
Eligibility Criteria
Inclusion Criteria: (Patients) * Alaska Native or American Indian person by self-report * eligible for or already receiving services at Southcentral Foundation (SCF) * age 18 years or older * daily smoking in the past 30-days * if other nicotine or tobacco products are used, cigarettes are main product used * planning to schedule an appointment with the Quit Tobacco Program to seek smoking cessation treatment in the next 30 days * willing to make a quit attempt within 30 days of enrollment in the Quit Tobacco Program * willing to have a blood test to inform their treatment * willing to try a pharmacologic treatment * willing to provide a saliva sample * has phone service * has access to broadband internet on mobile phone at home, work, or other location * has an Android or iPhone mobile phone compatible with the Smokerlyzer app (Staff) \- Staff participants of qualitative interviews to assess acceptability and feasibility of the intervention must be a health care professional at Southcentral Foundation (SCF), involved in the care of one of the participants of the study, that is their care team staff; including but not limited to: primary care providers, tobacco treatment specialists/health educators, pharmacists, nurse case managers, behavioral health consultants, certified medical assistants, and lab technicians. Exclusion Criteria: (Patients) * Participated in the prior study phase * participated in a cessation program during the past 3 months * their provider has not approved varenicline in their referral to the Quit Tobacco Program * has history of serious hypersensitivity or skin reactions to varenicline * has bleeding disorder or is currently receiving cancer treatment * questionable capacity or impaired decision-making capacity
Contact & Investigator
Georgia J Michlig, PhD
PRINCIPAL INVESTIGATOR
Southcentral Foundation
Frequently Asked Questions
Who can join the NCT06556238 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06556238 currently recruiting?
Yes, NCT06556238 is actively recruiting participants. Contact the research team at gmichlig@SouthcentralFoundation.com for enrollment information.
Where is the NCT06556238 trial being conducted?
This trial is being conducted at Anchorage, United States.
Who is sponsoring the NCT06556238 clinical trial?
NCT06556238 is sponsored by Southcentral Foundation. The principal investigator is Georgia J Michlig, PhD at Southcentral Foundation. The trial plans to enroll 50 participants.